Drug targets in human T-lymphotropic virus type 1 (HTLV-1) infection

Péter Boross, P. Bagossi, Irene T. Weber, J. Tőzsér

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Human T-lymphotropic virus type 1 (HTLV-1), the first known human retrovirus, induces various human diseases with a long latency period. The mechanism by which the virus causes diseases is still unknown. Studies indicate that viral replication is important at least for the development of HTLV-1 associated myelopathy, and therefore treatments based on our knowledge of human immunodeficiency virus type-1 (HIV-1) can be utilized to develop potent antiretroviral therapies targeting the replication enzymes reverse transcriptase, protease and integrase as well as the envelope glycoproteins. Furthermore, accessory gene products such as Tax and HBZ may also provide targets for chemotherapy. Treatment targeting these viral proteins may prevent the development of other HTLV-1-related diseases including adult T-cell leukemia, although such treatment may not be useful during the progression of the disease. This review describes the characteristics of HTLV-1 replication enzymes, envelope glycoproteins, and accessory proteins Tax and HBZ, and discusses the status of drug development strategies.

Original languageEnglish
Pages (from-to)159-171
Number of pages13
JournalInfectious Disorders - Drug Targets
Volume9
Issue number2
Publication statusPublished - 2009

Fingerprint

Human T-lymphotropic virus 1
Virus Diseases
Pharmaceutical Preparations
Glycoproteins
tax Gene Products
Tropical Spastic Paraparesis
Integrases
Adult T Cell Leukemia Lymphoma
RNA-Directed DNA Polymerase
Viral Proteins
Retroviridae
Enzymes
Therapeutics
Virus Replication
Disease Progression
HIV-1
Peptide Hydrolases
Drug Therapy
Genes

Keywords

  • Antiretroviral therapies
  • Envelope glycoproteins
  • HBZ
  • HTLV-1
  • Integrase
  • Protease
  • Reverse transcriptase
  • Tax

ASJC Scopus subject areas

  • Molecular Medicine
  • Microbiology (medical)
  • Pharmacology

Cite this

Drug targets in human T-lymphotropic virus type 1 (HTLV-1) infection. / Boross, Péter; Bagossi, P.; Weber, Irene T.; Tőzsér, J.

In: Infectious Disorders - Drug Targets, Vol. 9, No. 2, 2009, p. 159-171.

Research output: Contribution to journalArticle

@article{8fa90391e05a451285dcf11e8476f79e,
title = "Drug targets in human T-lymphotropic virus type 1 (HTLV-1) infection",
abstract = "Human T-lymphotropic virus type 1 (HTLV-1), the first known human retrovirus, induces various human diseases with a long latency period. The mechanism by which the virus causes diseases is still unknown. Studies indicate that viral replication is important at least for the development of HTLV-1 associated myelopathy, and therefore treatments based on our knowledge of human immunodeficiency virus type-1 (HIV-1) can be utilized to develop potent antiretroviral therapies targeting the replication enzymes reverse transcriptase, protease and integrase as well as the envelope glycoproteins. Furthermore, accessory gene products such as Tax and HBZ may also provide targets for chemotherapy. Treatment targeting these viral proteins may prevent the development of other HTLV-1-related diseases including adult T-cell leukemia, although such treatment may not be useful during the progression of the disease. This review describes the characteristics of HTLV-1 replication enzymes, envelope glycoproteins, and accessory proteins Tax and HBZ, and discusses the status of drug development strategies.",
keywords = "Antiretroviral therapies, Envelope glycoproteins, HBZ, HTLV-1, Integrase, Protease, Reverse transcriptase, Tax",
author = "P{\'e}ter Boross and P. Bagossi and Weber, {Irene T.} and J. Tőzs{\'e}r",
year = "2009",
language = "English",
volume = "9",
pages = "159--171",
journal = "Infectious Disorders - Drug Targets",
issn = "1871-5265",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Drug targets in human T-lymphotropic virus type 1 (HTLV-1) infection

AU - Boross, Péter

AU - Bagossi, P.

AU - Weber, Irene T.

AU - Tőzsér, J.

PY - 2009

Y1 - 2009

N2 - Human T-lymphotropic virus type 1 (HTLV-1), the first known human retrovirus, induces various human diseases with a long latency period. The mechanism by which the virus causes diseases is still unknown. Studies indicate that viral replication is important at least for the development of HTLV-1 associated myelopathy, and therefore treatments based on our knowledge of human immunodeficiency virus type-1 (HIV-1) can be utilized to develop potent antiretroviral therapies targeting the replication enzymes reverse transcriptase, protease and integrase as well as the envelope glycoproteins. Furthermore, accessory gene products such as Tax and HBZ may also provide targets for chemotherapy. Treatment targeting these viral proteins may prevent the development of other HTLV-1-related diseases including adult T-cell leukemia, although such treatment may not be useful during the progression of the disease. This review describes the characteristics of HTLV-1 replication enzymes, envelope glycoproteins, and accessory proteins Tax and HBZ, and discusses the status of drug development strategies.

AB - Human T-lymphotropic virus type 1 (HTLV-1), the first known human retrovirus, induces various human diseases with a long latency period. The mechanism by which the virus causes diseases is still unknown. Studies indicate that viral replication is important at least for the development of HTLV-1 associated myelopathy, and therefore treatments based on our knowledge of human immunodeficiency virus type-1 (HIV-1) can be utilized to develop potent antiretroviral therapies targeting the replication enzymes reverse transcriptase, protease and integrase as well as the envelope glycoproteins. Furthermore, accessory gene products such as Tax and HBZ may also provide targets for chemotherapy. Treatment targeting these viral proteins may prevent the development of other HTLV-1-related diseases including adult T-cell leukemia, although such treatment may not be useful during the progression of the disease. This review describes the characteristics of HTLV-1 replication enzymes, envelope glycoproteins, and accessory proteins Tax and HBZ, and discusses the status of drug development strategies.

KW - Antiretroviral therapies

KW - Envelope glycoproteins

KW - HBZ

KW - HTLV-1

KW - Integrase

KW - Protease

KW - Reverse transcriptase

KW - Tax

UR - http://www.scopus.com/inward/record.url?scp=67649196073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649196073&partnerID=8YFLogxK

M3 - Article

C2 - 19275704

AN - SCOPUS:67649196073

VL - 9

SP - 159

EP - 171

JO - Infectious Disorders - Drug Targets

JF - Infectious Disorders - Drug Targets

SN - 1871-5265

IS - 2

ER -